Natural History Study of Patients With Chronic Myelogenous Leukemia
Chronic Myeloid Leukemia (CML) Cohort
RATIONALE: Gathering information about patients with chronic myelogenous leukemia may help doctors learn more about the disease and find better methods of treatment and on-going care.
PURPOSE: This natural history study is collecting health information and disease-related information over time from patients with newly diagnosed chronic myelogenous leukemia.
研究概览
地位
条件
详细说明
OBJECTIVES:
- Determine the impact of current procedures for diagnosis, management, and follow-up on disease status of patients with newly diagnosed chronic myelogenous leukemia (CML).
- Determine the natural history of patients with CML who achieve response to imatinib mesylate.
- Determine the health perceptions, symptoms, insurance issues, and work issues of these patients.
- Determine whether medication compliance and planned dose reduction affect imatinib mesylate effectiveness in these patients.
- Determine the molecular and biologic factors associated with disease progression and good and poor response to imatinib mesylate in these patients.
OUTLINE: This is a longitudinal, prospective, cohort study.
Patients complete quality of life, functional status, medical and treatment history, and medication questionnaires at baseline and then every 6 months for 5 years.
Blood samples are collected at baseline and then every 6 months for 5 years. Specimens may be examined in the future in gene array studies and mutation analyses.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Impact of current procedures for diagnosis, management, and follow-up on disease status
大体时间:5 years
|
5 years
|
Natural history of patients with chronic myelogenous leukemia who achieve response to imatinib mesylate
大体时间:5 years
|
5 years
|
Health perceptions, symptoms, insurance issues, and work issues
大体时间:5 years
|
5 years
|
Affect of medication compliance and planned dose reduction on imatinib mesylate effectiveness
大体时间:5 years
|
5 years
|
Molecular and biologic factors associated with disease progression and good and poor response to imatinib mesylate
大体时间:5 years
|
5 years
|
合作者和调查者
调查人员
- 学习椅:Jerome Ritz, MD、Dana-Farber Cancer Institute
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 03-015
- P30CA006516 (美国 NIH 拨款/合同)
- CDR0000352370
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
白血病的临床试验
-
Shenzhen Second People's Hospital招聘中白血病 | 骨髓的 | 慢性的 | BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) | 积极的中国